Remote cognitive tests predict neurodegenerative biomarkers in the Insight 46 cohort
Alzheimer s & Dementia,
Journal Year:
2025,
Volume and Issue:
21(2)
Published: Feb. 1, 2025
Abstract
BACKGROUND
Alzheimer's
disease‐related
biomarkers
detect
pathology
years
before
symptoms
emerge,
when
disease‐modifying
therapies
might
be
most
beneficial.
Remote
cognitive
testing
provides
a
means
of
assessing
early
changes.
We
explored
the
relationship
between
neurodegenerative
and
cognition
in
cognitively
normal
individuals.
METHODS
remotely
deployed
13
computerized
Cognitron
tasks
255
Insight
46
participants.
generated
amyloid
load
positivity,
white
matter
hyperintensity
volume
(WMHV),
whole
brain
hippocampal
volumes
at
age
73,
plus
rates
change
over
2
years.
examined
Cognitron,
biomarkers,
standard
neuropsychological
tests.
RESULTS
Slower
response
time
on
delayed
recognition
task
predicted
positivity
(odds
ratio
[OR]
=
1.79,
confidence
interval
[CI]:
1.15,
2.95),
WMHV
(1.23,
CI:
1.00,
1.56).
Brain
atrophy
correlated
with
poorer
visuospatial
performance
(
b
‐0.42,
‐0.80,
‐0.05)
accuracy
immediate
‐0.01,
‐0.012,
‐0.001),
respectively.
Standard
tests
composites
(rho
0.50,
p
<
0.001).
DISCUSSION
correlates
supervised
assessments
holds
potential
for
studying
changes
associated
neurodegeneration.
Highlights
70%
Online
cohort
performed
set
remote
online
tasks.
Response
memory
status
(SUVR).
Accuracy
spatial
span
longitudinal
rate.
The
can
help
identify
AD‐related
deficits.
Language: Английский
Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A+T+ (A+T1+) Alzheimer’s Disease
Ioanna Tsantzali,
No information about this author
Athanasia Athanasaki,
No information about this author
F. Boufidou
No information about this author
et al.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(12), P. 2904 - 2904
Published: Dec. 20, 2024
Background:
Alzheimer’s
disease
(AD)
may
present
with
pure
(typical
or
atypical)
and
mixed
phenotypes,
sometimes
causing
difficulties
in
(differential)
diagnosis.
In
order
to
achieve
a
diagnostic
accuracy
as
high
possible,
the
diagnosis
of
AD
during
life
depends
on
various
biomarkers,
including
cerebrospinal
fluid
(CSF)
biomarkers.
Methods:
Classical
CSF
biomarkers
were
determined
total
61
patients,
classified
both
beta
amyloid-
tau-positive
A+T+
(or
A+T1+
according
recently
revised
Alzheimer
Association
criteria
for
staging
AD).
Twenty
one
these
patients
fulfilled
(mixed
Lewy
bodies,
cerebrovascular
disease,
normal
pressure
hydrocephalus),
whilst
40
had
AD.
Results:
Patients
did
not
differ
respect
gender,
education,
duration,
cognitive
status.
After
controlling
confounding
factors,
no
difference
was
observed
between
groups
Aβ42
Aβ42/Aβ40
levels.
Although
by
definition,
abnormal
(increased)
levels
phospho-tau181,
group
presented
lower
(less
abnormal)
phospho-tau181
tau
compared
group.
Conclusions:
comparable
status,
cases
proteins
and,
if
close
cut-off
values,
uncertainty
be
increased.
Language: Английский